Aprogen Biologics (003060) Price & Analysis

003060 Stock Chart & Stats

$1,335.00-$45.00(-3.26%)

At close: Oct 30 4:00 PM EDT

Day’s Range: $1,333.00 - $1,382.00
52-Week Range: $1,333.00 - $9,945.00
Previous Close: $1,380.00
Volume: N/A
Average Volume (3M): 106.01K
Market Cap: KRW 40.05B
Enterprise Value: KRW 294.17B
Total Cash (Recent Filing): KRW 22.70B
Total Debt (Recent Filing): KRW 210.84B
Price to Earnings (P/E): ―
Beta: 0.10
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Revenue growth provides evidence that Aprogen retains some commercial traction despite severe losses. Continued top-line expansion can support operating leverage and improve the economics of its biologics portfolio if growth is sustained and eventually matched by better cost control.

Improving Net Loss

The substantially smaller net loss indicates some improvement from the prior year, even though profitability remains deeply negative. If this direction continues, it could reduce the pace of capital consumption and create a more credible path toward financial stabilization.

Cash Burn Below Accounting Loss

Free cash flow being less negative than net income suggests non-cash charges or working-capital effects are reducing cash burn relative to reported losses. This offers a limited cash-conversion benefit, although the company still needs to improve operations to generate positive cash flow.

Bears Say

Severe Unprofitability

Negative gross profit and exceptionally deep operating and net margins indicate that the current business model is not covering its underlying costs. Persistent losses weaken internal funding capacity and make revenue growth less valuable until pricing, costs, or product economics improve.

Persistent Cash Burn

Negative operating and free cash flow show that Aprogen is consuming cash rather than funding operations internally. Continued burn can increase reliance on external financing, constrain investment in biologics development, and reduce flexibility if losses persist over coming quarters.

Rising Leverage

Debt now slightly exceeds equity and leverage has deteriorated materially from 2024 while the company remains loss-making. This combination increases sensitivity to further losses and refinancing needs, potentially limiting management's ability to fund growth without additional financial pressure.

003060 FAQ

What was Aprogen Biologics’s price range in the past 12 months?

Aprogen Biologics lowest stock price was $1333.00 and its highest was $9945.00 in the past 12 months.

What is Aprogen Biologics’s market cap?

Aprogen Biologics’s market cap is ₩40.05B.

When is Aprogen Biologics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Aprogen Biologics’s earnings last quarter?

Aprogen Biologics released its earnings results on Aug 19, 2026. The company reported -$999.481 earnings per share for the quarter.

Is Aprogen Biologics overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Aprogen Biologics pay dividends?

Aprogen Biologics does not currently pay dividends.

What is Aprogen Biologics’s EPS estimate?

Aprogen Biologics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aprogen Biologics have?

Aprogen Biologics has 30,079,500 shares outstanding.

What happened to Aprogen Biologics’s price movement after its last earnings report?

Aprogen Biologics reported an EPS of -$999.481 in its last earnings report. Following the earnings report the stock price went down -2.156%.

Which hedge fund is a major shareholder of Aprogen Biologics?

Currently, no hedge funds are holding shares in KR:003060

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description